<i>In vitro</i> antimicrobial activity and resistance mechanisms of cefiderocol against clinical carbapenem-resistant gram-negative bacteria.

ABSTRACT:

Background

The rise of carbapenem-resistant gram-negative bacteria (CRGNB) necessitates new therapeutic options such as cefiderocol.

Objective

To evaluate the in vitro efficacy of cefiderocol against clinical CRGNB and investigate associated resistance mechanisms.

Methods

A total of 370 CRGNB isolates were analyzed. Minimum inhibitory concentration (MIC) values were determined, and whole genome sequencing, efflux pump inhibition assays, and RT-qPCR were conducted to assess resistance-related mutations, gene loss, and expression changes.

Results

Cefiderocol demonstrated potent in vitro activity, with high susceptibility rates in C. freundii (100%), K. pneumoniae (93.3%), and E. hormaechei (92.2%), and notable activity against <

SUBMITTER: Yan R 

PROVIDER: S-EPMC12532133 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature